Adecto Pharmaceuticals is a pre-clinical stage company developing a treatment for cancers that do not respond to conventional immunotherapy.

Adecto's approach is to reprogram a larger set of the patient’s immune cells than conventional immunotherapy can achieve, resulting in a more powerful immune response against a variety of aggressive tumors.

Adecto is built on its founders' 30+ years of research hunting down molecules that can be safely targeted to stop both primary cancer growth and metastases.